As of May 25
| +0.01 / +0.17%|
The 6 analysts offering 12-month price forecasts for Regulus Therapeutics Inc have a median target of 20.50, with a high estimate of 35.00 and a low estimate of 15.00. The median estimate represents a +249.83% increase from the last price of 5.86.
The current consensus among 8 polled investment analysts is to Buy stock in Regulus Therapeutics Inc. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.